Stress signals utilize multiple pathways to stabilize p53

Molecular and Cellular Biology

Volumn 20, Issue 9, 2000, Pages 3224-3233

  Ashcroft, Margaret ^a   Taya, Yoichi ^b   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; STRESS; TRANSCRIPTION REGULATION;

BLOTTING, NORTHERN; CAMPTOTHECIN; CELLS, CULTURED; CHELATING AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DACTINOMYCIN; DEFEROXAMINE; DOWN-REGULATION; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; IMMUNOBLOTTING; MICROSCOPY, FLUORESCENCE; NUCLEAR PROTEINS; NUCLEIC ACID SYNTHESIS INHIBITORS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SERINE; STRESS; TIME FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034003005     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.20.9.3224-3233.2000     Document Type: Article

References (59)

1. An, W. G., M. Kanekal, M. C. Simon, E. Maltepe, M. V. Blagosklonny, and L. M. Neckers. 1998. Stabilization of wild-type by hypoxia-inducible factor lalpha. Nature 392:405-408.
2. waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory loop. Oncogene 18:1081-1091.
3. Ashcroft, M., M. H. Kubbutat, and K. H. Vousden. 1999. Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 19:1751-1758.
4. Ashcroft, M., and K. H. Vousden. 1999. Regulation of p53 stability. Oncogene 18:7637-7643.
5. Banin, S., L. Moyal, S.-Y. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinskj, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
6. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. Mdm-2 expression is induced by wild type p53 activity. EMBO J. 12:461-468.
7. ARF links the tumour suppressors RB and p53. Nature 395:124-125.
8. Bates, S., and K. H. Vousden. 1996. p53 in signalling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:1-7.
9. Blattner, C., A. Sparks, and D. Lane. 1999. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 19:3704-3713.
10. Blattner, C., E. Tobiasch, M. Litfen, H. J. Rahmsdorf, and P. Herrlich. 1999. DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18:1723-1732.
11. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-556.
12. Bulavin, D., S. Saito, M. C. Hollander, K. Sakaguchi, C. W. Anderson, E. Appella, and A. J. Fornace, Jr. 1999. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18:6845-6854.
13. Canman, C. E., D.-S. Lim, K. A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M. B. Kastan, and J. D. Siliciano. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679.
14. Choi, J., and L. A. Donehower. 1999. p53 in embryonic development: maintaining a fine balance. Cell. Mol. Life Sci. 55:38-47.
15. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
16. de Stanchina, E., M. E. McCurrach, F. Zindy, S. Y. Shieh, G. Ferbeyre, A. V. Samuelson, C. Prives, M. F. Roussel, C. J. Sherr, and S. W. Lowe. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12: 2434-2442.
17. Elenbaas, B., M. Dobbelstein, J. Roth, T. Shenk, and A. J. Levine. 1996. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2:439-451.
18. Kreedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288-7293.
19. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
20. Honda, R., H. Tanaka, and H. Vasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
21. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18: 22-27.
22. Hsiang, Y. H., R. Hertzberg, S. Hecht, and L. F. Liu. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-14878.
23. Hupp, T. R., and D. P. Lane. 1994. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:865-875.
24. Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
25. Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95:8292-8297.
26. ARF Cell 91:649-659.
27. Kessis, T. D., R. J. Slebos, W. G. Nelson, M. B. Kastan, B. S. Plunkett, S. M. Han, A. T. Lorincz, L. Hedrick, and K. R. Cho. 1993. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90:3988-3992.
28. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
29. Kubbutat, M. H. G., and K. H. Vousden. 1998. Keeping an old friend under control: regulation of p53 stability. Mol. Med. Today 4:250-256.
30. Lain, S., C. Midgley, A. Sparks, E. B. Lane, and D. P. Lane. 1999. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODS. Exp. Cell Res. 248:457-472.
31. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
32. Ljungman, M., F. Zhang, F. Chen, A. J. Rainbow, and B. C. McKay. 1999. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18:583-592.
33. Lohrum, M. A. E., M. Ashcroft, M. H. G. Kubbutat, and K. H. Vousden. 2000. Identification of a cryptic nucleolar-localization signal in MDM2. Nat. Cell Biol. 2:179-181.
34. Middeler, G., K. Zerf, S. Jenovai, A. Thulig, M. Tschodrich-Rotter, U. Kubitscheck, and R. Peters. 1997. The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene 14:1407-1417.
35. Midgley, C. A., C. J. Fisher, J. Bartek, B. Vojtesek, D. P. Lane, and D. M. Barnes. 1992. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in E. coli. J. Cell Sci. 101:183-189.
36. Montes de Oca Luna, R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
37. Palmero, I., C. Pantoja, and M. Serrano. 1998. p19ARF links the tumour suppressor p53 to Ras. Nature 395:125-126.
38. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
39. Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554-564.
40. Sakaguchi, K., J. E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C. W. Anderson, and E. Appella. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831-2841.
41. Shaulsky, G., N. Goldfinger, A. Ben-Ze'ev, and V. Rotter. 1990. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10:6565-6577.
42. Shaulsky, G., N. Goldfinger, M. S. Tosky, A. Levine, and V. Rotter. 1991. Nuclear localization is essential for the activity of p53 protein. Oncogene 6: 2055-2065.
43. Sherr, C. J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:2984-2991.
44. Shieh, S.-Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
45. Shieh, S. Y., Y. Taya, and C. Prives. 1999. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20. requires tetramerization. EMBO J. 18:1815-1823.
46. Siliciano, J. D., C. E. Canman, Y. Taya, K. Sakaguchi, E. Appella, and M. B. Kastan. 1997. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:3471-3481.
47. Stommel, J. M., N. D. Marchenko, G. S. Jimenez, U. M. Moll, T. J. Hope, and G. M. Wahl. 1999. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1660-1672.
48. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
49. Tao, W., and A. J. Levine. 1999. Nudeocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96:3077-3080.
50. ARF stabilizes p53 by blocking nucleocytoplastnic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA 96:6937-6941.
51. Tibbetts, R. S., K. M. Brumbaugh, J. M. Williams, J. N. Sarkaria, W. A. Cliby, S. Y. Shieh, Y. Taya, C. Prives, and R. T. Abraham. 1999. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13: 152-157.
52. Unger, T., T. Juven-Gershon, E. Moallem, M. Berger, R. Vogt Sionov, G. Lozano, M. Oren, and Y. Haupt. 1999. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18:1805-1814.
53. Waldman, T., K. W. Kinzler, and B. Vogelstein. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
54. Weber, J. D., L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1:20-26.
55. Wu, L., and A. J. Levine. 1997. Differential regulation of the p21/WAF-1 and mdm2 genes after high dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 3:441-451.
56. Wu, X. W., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53 mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
57. Yokoyama, Y., K. Niwa, and T. Tamaya. 1992. Scattering of the silver-stained proteins of nucleolar organizer regions in Ishikawa cells by actinomycin D. Exp. Cell Res. 202:77-86.
58. Zhang, Y., and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of Mdm2 and p53. Mol. Cell 3:579-591.
59. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424-2433.